{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2692768"],"location":["China"],"study_start_month":["5"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"The efficacy and safety of regorafenib taking 5 days and stop 2 days for the third-line treatment in mRCR patients","description":"Interventions: experimental group:Regorafenib, taking 5 days and stop 2 days;control group:Regorafenib, once a day\nPrimary outcome(s): Progression-Free Survival\nStudy Design: Parallel","dates":{"creation":"2020-05-15"},"accession":"2692768","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2000032297"]}}